Merck & Co. reports Q2 results
WHITEHOUSE STATION, N.J. Merck & Co. reported sales of $5.9 billion for second quarter 2009 in an earnings release Tuesday, a decrease of 3% from second quarter 2008.
That would have meant a 3% increase over last year were it not for the effect of foreign exchange rates, the company said. Meanwhile, net income for the quarter was $1.6 billion, compared with $1.8 billion for second quarter 2008.
“Driven by strong growth in our newest pharmaceutical products and in Singulair, Merck delivered solid operational results for the second quarter,” president, CEO and chairman Richard Clark said in a statement. “We’re committed to maximizing the therapeutic and commercial potential of our in-line and newly launched products.”
Singulair (montelukast sodium) is used to treat asthma.